Advertisement FDA accepts for filing Bayer's sBLA for Betaconnect to treat RRMS - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDA accepts for filing Bayer’s sBLA for Betaconnect to treat RRMS

The US Food and Drug Administration (FDA) has accepted the filing Bayer's supplemental biologics license application (sBLA) for Betaconnect (proposed name), another delivery option for Betaseron (interferon beta-1b), a treatment for relapsing-remitting multiple sclerosis (RRMS).

Betaseron is a prescription medicine used to reduce the number of relapses in people with relapsing forms of MS, which includes people who have had their first symptoms of multiple sclerosis and have an MRI consistent with multiple sclerosis.

The company said that Betaseron will not cure MS but may decrease the number of flare-ups of the disease.

Bayer HealthCare Pharmaceuticals vice-president and head US Medical Affairs Dr Dario Mirski said: "This filing underscores Bayer’s continued, longstanding commitment to meeting the needs of patients taking BETASERON to treat their relapsing forms of MS."

The company said that most common side effects of Betaseron include low white blood cell count, increases in your liver enzymes, headache, increase in your muscle tension, pain, rash, problems sleeping, stomach pain, weakness.